According to the Zhitong Finance APP, Fangsheng Pharmaceutical (603998.SH) announced that on September 22, 2025, the company's research and development of the traditional Chinese medicine innovative drug Zhilong Tongluo Pian obtained the Phase II clinical research report. Indications: It has the effects of invigorating qi and promoting blood circulation, removing stasis and unblocking collaterals, and is suitable for treating the recovery period of cerebral infarction (ischemic stroke) with meridian obstruction, collateral damage, loss of motor function, and symptoms caused by qi deficiency and blood stasis such as unilateral numbness, pain, hemiplegia, slurred speech, facial asymmetry, fatigue, memory decline, and insomnia.

The safety results of the trial showed that there was no statistically significant difference in the comparison of severe adverse events and adverse reactions between groups, and all severe adverse events in each group were related to the recurrence of acute cerebral infarction, with no fatalities among the subjects. This indicates that Zhilong Tongluo Pian has good safety. Zhilong Tongluo Pian has shown a reduction in the modified Rankin scale with no significant disability, improves the degree of neurological dysfunction, enhances daily living abilities, and improves stroke-specific quality of life. It is an effective formula for symptoms caused by qi and blood stasis in the meridians leading to upper limb paralysis, facial asymmetry, shortness of breath, fatigue, and spontaneous sweating, with a trend of efficacy in improving lower limb paralysis, slurred speech or inability to speak, sensory reduction or loss, and pale complexion, and is safe and convenient. The efficacy of the low-dose group is comparable to that of the high-dose group, and it is recommended that the low-dose group continue to conduct Phase III clinical research